title: Differences between treatment guidelines--Germany.
abstract: When looking at different treatment guidelines the topics most debated for Crohn's disease are the following: (a) the use of mesalamine for remission induction and maintenance in mild to moderate Crohn's disease; (b) the early use of anti-TNF antibodies in Crohn's disease with or without classical immunomodulators for remission induction, and (c) remission induction in steroid-refractory disease with anti-TNF antibodies or calcineurin inhibitors. The topics mentioned above will be discussed with regard to the statements of the German Gastroenterology Association (DGVS) on the basis of the underlying evidence.
authors.affiliation: Innere Medizin, Asklepios Klinik Nord, Betriebsteil Heidelberg, Hamburg, Germany.
authors.forename: Klaus R
authors.initials: KR
authors.lastname: Herrlinger
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D005858:Germany; D006801:Humans; D000069285:Infliximab; D019804:Mesalamine / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
chemical_list: D000911:Antibodies, Monoclonal; D019804:Mesalamine; D000069285:Infliximab